Academic literature on the topic 'Dithranol'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dithranol.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Dithranol"
&NA;. "Dithranol." Reactions Weekly &NA;, no. 772 (October 1999): 7. http://dx.doi.org/10.2165/00128415-199907720-00021.
Full text&NA;. "Dithranol." Reactions Weekly &NA;, no. 440 (February 1993): 8. http://dx.doi.org/10.2165/00128415-199304400-00030.
Full textMahrle, Gustav. "Dithranol." Clinics in Dermatology 15, no. 5 (September 1997): 723–37. http://dx.doi.org/10.1016/s0738-081x(97)00019-9.
Full text&NA;. "Dithranol." Reactions Weekly &NA;, no. 400 (May 1992): 7. http://dx.doi.org/10.2165/00128415-199204000-00022.
Full textChavali, Krishnadutt H., and Harish Dasari. "Dithranol." American Journal of Forensic Medicine and Pathology 33, no. 3 (September 2012): 253–55. http://dx.doi.org/10.1097/paf.0b013e3182198659.
Full text&NA;. "Dithranol." Reactions Weekly &NA;, no. 1388 (February 2012): 14. http://dx.doi.org/10.2165/00128415-201213880-00052.
Full textMelhorn, S. "Dithranol." Der Hautarzt 68, no. 5 (April 11, 2017): 421–23. http://dx.doi.org/10.1007/s00105-017-3977-5.
Full textC, Anahera, and Kahurangi S. "Development of Dithranol overloaded hard Lipid Nanoparticles." International Journal of Pharmacy and Biomedical Engineering 2, no. 3 (December 25, 2015): 5–8. http://dx.doi.org/10.14445/23942576/ijpbe-v2i3p102.
Full textPrins, M., O. Q. J. Swinkels, J. M. Mommers, M. J. P. Gerritsen, and P. G. M. Valk. "Dithranol treatment of psoriasis in dithranol-sensitive patients." Contact Dermatitis 41, no. 2 (May 1, 2007): 116–17. http://dx.doi.org/10.1111/j.1600-0536.1999.tb06250.x.
Full textLegradi, Adam, Karolina Dulka, Gábor Jancsó, and Karoly Gulya. "Orofacial skin inflammation increases the number of macrophages in the maxillary subregion of the rat trigeminal ganglion in a corticosteroid-reversible manner." Cell and Tissue Research 382, no. 3 (July 21, 2020): 551–61. http://dx.doi.org/10.1007/s00441-020-03244-3.
Full textDissertations / Theses on the topic "Dithranol"
McBride, Sandra R. "The inflammatory response to dithranol." Thesis, University of Newcastle upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.421173.
Full textLubwika, Paul. "A stability study of dithranol in solution, formulations and in normal and psoriatic skin." Thesis, Robert Gordon University, 1994. http://hdl.handle.net/10059/2348.
Full textPriprem, Aroonsri. "The development and evaluation of a hydrogel drug delivery system for dithranol." Thesis, Robert Gordon University, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278936.
Full textReindl, Hans. "Synthese und Charakterisierung bei der biologischen Aktivität neuer 10-Acylderivate des Antipsoriatikums Dithranol /." [S.l. : s.n.], 1999. http://www.gbv.de/dms/bs/toc/301413681.pdf.
Full textMilner, Sarah Elizabeth. "The effects of the anti-psoriatic agent dithranol on intracellular calcium signalling in keratinocytes." Thesis, University of Newcastle Upon Tyne, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501057.
Full textTait, Russell John, and mikewood@deakin edu au. "Development and application of a microelectrode based scanning voltammetric detector." Deakin University. School of Physical and Chemical Sciences, 1991. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20060720.100447.
Full textSavian, Ana Luiza. "DESENVOLVIMENTO DE NANOCÁPSULAS CONTENDO DITRANOL E SUA INCORPORAÇÃO EM FORMULAÇÃO SEMISSÓLIDA DE BASE AQUOSA." Universidade Federal de Santa Maria, 2012. http://repositorio.ufsm.br/handle/1/5979.
Full textDithranol is very effective drug for the topical treatment of psoriasis. However, it has some adverse effects, such as irritation and stain in the skin that difficult its application and patient adherence to treatment. Its instability to light, high pH values, metals and the presence of oxygen, configure as a limiting step for use. So, the inclusion of drug in nanocarriers was the main objective of this work. Lipid core nanocapsules and nanoemulsions containing 0.5 mg/mL of dithranol and 0.05% of EDTA or 0.02% of ascorbic acid were prepared by interfacial deposition of preformed polymer and spontaneous emulsification methods, respectively, and evaluated in relation to its physicochemical characteristics (drug content, encapsulation efficiency, pH, mean size, polydispersity index and zeta potential). The nanocapsules, after preparation, showed satisfactory characteristics: drug content near to the theoretical concentration, encapsulation efficiency about 100%, nanometric mean size (220- 250 nm), polydispersity index below 0.25, negative zeta potential, and pH values from 5.6 to 4.4. Instead, low drug content was verified for the nanoemulsions (approximately 80%) after preparation. In photodegradation study against UVA light it was observed a higher stability of the dithranol-loaded nanocapsules comparing to solution containing the free drug (t1/2 = 4 and 1 h for nanocapsule and free drug solution containing EDTA, respectively; t1/2 = 17 and 7,5 h for nanocapsule and free drug solution containing ascorbic acid, respectively). Irritation test by HET-CAM method was conducted to evaluate the safety of the formulations. From the results it was found that nanoencapsulation of the drug decreased its toxicity compared to the effects observed for free drug. Subsequently, hydrogels containing nanocapsules were prepared employing Carbopol® 940 and Aristoflex® AVC as gel-forming polymers. The semisolid formulations showed suitable properties for topical application and higher stability when compared to nanocapsules suspensions and the hydrogel containing the free drug. Furthermore, a higher stability of dithranol was verified for hydrogels prepared with Aristoflex® AVC.
O ditranol é um fármaco muito eficaz no tratamento tópico da psoríase. Entretanto, apresenta alguns efeitos adversos, como irritação e manchas na pele que dificultam sua utilização e adesão dos pacientes ao tratamento. Sua instabilidade frente à luz, altos valores de pH, metais e a presença de oxigênio, configuram, também, um passo limitante para o seu uso. Desta forma, a inclusão do fármaco em nanocarreadores constituiu o principal objetivo deste trabalho. Nanocápsulas de núcleo lipídico e nanoemulsões contendo 0,5 mg/mL de ditranol e 0,05% de EDTA ou 0,02% de ácido ascórbico foram preparadas pelos métodos de deposição interfacial do polímero pré-formado e emulsificação espontânea, respectivamente, e avaliadas em relação as suas características físico-químicas (teor de fármaco, eficiência de encapsulamento, pH, diâmetro médio de partícula, polidispersão e potencial zeta). As nanocápsulas, após preparação, apresentaram características satisfatórias: teor de fármaco próximo ao teórico, eficiência de encapsulamento de, aproximadamente, 100%, diâmetro de partícula na faixa nanométrica (220-250 nm), índice de polidispersão abaixo de 0,25, potencial zeta negativo e valores de pH de 5,6 a 4,4. Ao contrário, um baixo teor de fármaco foi verificado para as nanoemulsões (aproximadamente, 80%) após preparação. No estudo de fotodegradação frente à luz UVA se observou uma maior estabilidade do fármaco nas nanocápsulas em comparação à solução do fármaco livre (t1/2 = 4 e 1 hora para a nanocápsula e solução do fármaco livre contendo EDTA, respectivamente; t1/2 = 17 e 7,5 horas para a nanocápsula e solução do fármaco livre contendo ácido ascórbico, respectivamente). O ensaio de irritação pelo método de HET-CAM foi realizado para a avaliação da segurança das formulações. A partir dos resultados verificou-se que a encapsulação do fármaco diminuiu sua toxicidade em relação aos efeitos observados para o fármaco livre. Posteriormente, hidrogéis contendo as nanocápsulas foram preparados empregando-se Carbopol® 940 e Aristoflex® AVC como polímeros formadores de gel. As formulações semissólidas desenvolvidas apresentaram propriedades adequadas para a aplicação tópica e maior estabilidade quando comparadas às suspensões de nanocápsulas e ao hidrogel contendo o fármaco livre. Além disso, uma maior estabilidade do ditranol foi verificada para os hidrogéis preparados com Aristoflex® AVC.
Wohlrab, Lukas. "Der Einfluß von Harnstoff auf die antiproliferative Wirkung von Dithranol /." 1998. http://www.gbv.de/dms/bs/toc/239950208.pdf.
Full text杜春江. "Synthetic study of 10-substituted dithranol via Base-Catalyed Diels-Alder Cycloaddition." Thesis, 1992. http://ndltd.ncl.edu.tw/handle/91230820188146637939.
Full textBook chapters on the topic "Dithranol"
Kucharekova, M., PC M. van de Kerkhof, J. Schalkwijk, and P. G. M. van der Valk. "Dithranol." In Irritant Dermatitis, 317–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-31294-3_34.
Full textGloor, M. "Dithranol, Vitamin D3-Analoga und 8-Methoxypsoralen." In Dermatologische Externatherapie, 361–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-58308-7_14.
Full textBernd, A., H. Holzmann, W. Ch Marsch, B. Kureleć, S. Britvić, and W. E. G. Müller. "Cytotoxische und anti-mutagene Eigenschaften von Dithranol (= Cignolin) in vitro." In Dermatologie und Rheuma, 545–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72668-2_61.
Full textMustakallio, K. K. "Treatment of Psoriasis with Dithranol (Cignolin, Anthralin) and Other Hydroxyanthrones." In Dermatology in Five Continents, 92–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-83360-1_13.
Full textPrzybilla, B., P. Kaudewitz, and K. Bieber. "Harnstoff in Kombination mit Dithranol zur Therapie der Psoriasis vulgaris." In Harnstoff in der Dermatologie, 54–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83754-8_9.
Full textBernd, A., H. Holzmann, H. Ch Schröder, and W. E. G. Müller. "Wirkung von Dithranol und Steinkohlenteer auf den nukleo-cytoplasmatischen Transport der mRNA." In Dermatologie und Rheuma, 548–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72668-2_62.
Full textKanerva, L., and J. Lauharanta. "Variable Effects of Irritants (Methylmethacrylate, Terphenyls, Dithranol and Methylglyoxal-bis-Guanylhydrazone) on the Fine Structure of the Epidermis." In Archives of Toxicology, 455. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71248-7_93.
Full textKosma, V. M., Y. Collan, A. Naukkarinen, M. L. Aalto, and P. Männistö. "Histopathological and Morphometrical Analysis Applied to Skin Changes in NMRI Mice Induced by Dithranol (Anthranil) and its Acyl Analogs." In Archives of Toxicology, 451–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71248-7_92.
Full text"Coal tar and Dithranol." In Meyler's Side Effects of Drugs, 487–89. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01715-7.
Full text